Key Takeaways
- • Canada's government unveiled two initiatives to address venture capital funding gaps: a $1 billion venture and growth capital catalyst initiative and a $750 million early and growth stage investment strategy, aimed at deploying roughly $5 billion into start-ups and innovation.
- • The Canadian Investment Summit presented 160 projects to domestic and foreign institutional investors, with an ambition to raise $1 trillion over five years, which the article questions as unrealistic.
- • Canada's population grew by roughly six million (about 14 per cent) over the last decade while GDP per capita has hardly increased, according to the article.
- • The article argues large pension plans should integrate venture capital as a distinct early-stage and high-growth allocation rather than hiding it within private equity, citing innovation as a risk management tool.
- • Amplitude Ventures says life sciences has enough ideas to build multi-billion-dollar businesses, but funding is lacking, and $200 million in federal life sciences support is seen as insufficient to move GDP growth.
Summary
At the Canadian Investment Summit, domestic and foreign institutional investors were presented with a list of 160 projects earmarked for investment. The article, published by Benefits Canada, argues that while infrastructure underinvestment makes these projects a necessity, they are not sufficient on their own to create a thriving economy. It contends that Canada needs a stronger venture capital sector to drive innovation and productivity growth.
The article notes that Canada's population has grown by roughly six million people, or about 14 per cent, over the last decade, while GDP per capita has hardly risen. It argues that population growth mainly generates demand for basic needs such as housing, food, education and healthcare, which do not drive GDP growth above population growth.
The federal government recently unveiled two initiatives to address the shortage of institutional capital in venture markets: the venture and growth capital catalyst initiative, with $1 billion, and the early and growth stage investment strategy, with $750 million. Both aim to invest in early-stage companies and unlock private-sector funding so that approximately $5 billion can be deployed into start-ups and innovation. The article questions whether the summit's goal of raising $1 trillion over five years is realistic, noting that other markets have raised $5 billion in a single summer.
The article observes that large pension plans favor large cash-flow-generating assets over greenfield operations, which makes the summit's infrastructure projects attractive to them, but leaves open how venture-backed companies moving from ideation to exit will attract capital. It cites Amplitude Ventures, a medical VC firm, which says life sciences has enough ideas to build sustainable multi-billion-dollar businesses, but that the funding is not there. The article says $200 million in federal life sciences funding is welcome but will have limited impact on Canadian GDP growth.
The article argues that venture capital can introduce new business models that pressure incumbent companies, which are the types of businesses large pension funds often buy for their cash flows. It concludes that pension plans should invest in both Canada's economic infrastructure and in innovation, integrating early-stage and high-growth start-ups as a distinct focus rather than keeping venture capital within private equity portfolios.
The article notes that Canada's population has grown by roughly six million people, or about 14 per cent, over the last decade, while GDP per capita has hardly risen. It argues that population growth mainly generates demand for basic needs such as housing, food, education and healthcare, which do not drive GDP growth above population growth.
The federal government recently unveiled two initiatives to address the shortage of institutional capital in venture markets: the venture and growth capital catalyst initiative, with $1 billion, and the early and growth stage investment strategy, with $750 million. Both aim to invest in early-stage companies and unlock private-sector funding so that approximately $5 billion can be deployed into start-ups and innovation. The article questions whether the summit's goal of raising $1 trillion over five years is realistic, noting that other markets have raised $5 billion in a single summer.
The article observes that large pension plans favor large cash-flow-generating assets over greenfield operations, which makes the summit's infrastructure projects attractive to them, but leaves open how venture-backed companies moving from ideation to exit will attract capital. It cites Amplitude Ventures, a medical VC firm, which says life sciences has enough ideas to build sustainable multi-billion-dollar businesses, but that the funding is not there. The article says $200 million in federal life sciences funding is welcome but will have limited impact on Canadian GDP growth.
The article argues that venture capital can introduce new business models that pressure incumbent companies, which are the types of businesses large pension funds often buy for their cash flows. It concludes that pension plans should invest in both Canada's economic infrastructure and in innovation, integrating early-stage and high-growth start-ups as a distinct focus rather than keeping venture capital within private equity portfolios.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.